AI Longevity Daily

Today’s Summary

A multi-ingredient anti-aging supplement showed improvements in arterial function in a human trial.
A mouse study found that increasing or decreasing a protein in brain support cells can slow whole-body aging.
The supplement trial was small, had a high dropout rate, and was funded by the manufacturer — independent verification is still needed.

🔥 Top 10 Today

1. NOVOS Core, an anti-aging supplement, improved arterial function in a randomized controlled trial

As reported by Lifespan.io , NOVOS Core — a multi-ingredient supplement — was tested by a University of Surrey research team in a randomized, double-blind, placebo-controlled trial. 43 participants completed the primary analysis (24 in the supplement group, 19 in the placebo group). Flow-mediated dilation (FMD — how much an arm artery expands after blood flow is restored, reflecting blood vessel wall elasticity) improved by about 2.6 percentage points in the supplement group after six months, while the placebo group saw almost no change. Systolic blood pressure dropped by roughly 8.5 mmHg, with an adjusted between-group difference of 6.1 mmHg. Two major caveats worth noting: nearly a third of participants dropped out, the placebo group was about seven years older on average than the supplement group, and NOVOS both supplied the supplements and co-funded the study. It’s also unclear which ingredient is doing the work — treat these results cautiously until an independent team replicates them.

2. A new epigenetics review argues aging probably has multiple rate-limiting steps, not one root cause

As reported by Longevity.Technology , a review published in the journal Aging introduces a “polycentric aging framework,” arguing that aging is driven by several relatively independent processes rather than a single mechanism. Epigenetic regulation — the system that switches genes on and off without changing the DNA sequence itself — is considered by the authors to be the most broadly coordinating layer, though not the only rate-limiting one. The review also points out that existing epigenetic clocks (tools that estimate biological age from chemical markers on DNA) may not distinguish between harmful changes and compensatory ones — in the CALERIE dietary restriction trial and the DO-HEALTH fish oil trial, different clocks gave inconsistent readings. This is a conceptual review, not an experimental study, and the authors explicitly call for longitudinal research and controlled interventions. 🧬

3. FGF13, a protein in brain astrocytes, can trigger or slow whole-body aging in mice when its levels are changed

As reported by Lifespan.io , a study published in Aging Cell found that boosting expression of FGF13 — a protein in astrocytes, the brain cells that support and protect neurons — brought aging mice’s spatial memory test performance close to that of young mice. Blood levels of inflammatory signaling molecules dropped significantly, and cellular senescence in multiple organs (outside the heart) was reduced. Since FGF13 can’t be secreted out of cells, the researchers think its systemic effect is mediated through autophagy — the mechanism cells use to clear out old, damaged components. Results are currently mouse-only; non-human primate validation is needed before any human application, and the paper doesn’t propose any specific delivery route. 🐭

4. Voyager Therapeutics is debuting two Alzheimer’s tau-targeting therapies at a clinical conference in November

As reported by Longevity.Technology , Voyager Therapeutics will present two approaches targeting tau — the protein that forms tangles in the brain cells of Alzheimer’s patients — at the November CTAD conference. VY1706 is a gene therapy designed to cross the blood-brain barrier after IV injection and suppress tau production directly in the brain; it’s still in the study design phase with no human dosing yet. VY7523 is an antibody targeting existing tau protein, currently in the baseline enrollment phase of a Phase 1/2 dose-escalation trial, with no efficacy data whatsoever. Both posters report zero outcome numbers — this announcement is essentially a public declaration of research starting points. Whether tau therapies actually work remains an open question for every approach out there.

5. Dog Aging Project data from 41,000 companion dogs shows dog lifespans track human mortality by state — after controlling for body size

As reported by Longevity.Technology , the Dog Aging Project analyzed survival data from over 41,000 dogs published in GeroScience. After adjusting for size, breed, and sex, state-level canine mortality rates showed a significant positive correlation with human mortality rates — Tennessee, Oklahoma, and Kentucky were on the high end, while Hawaii and California came in low. Interestingly, what looked like a “rural penalty” disappeared once you accounted for rural dogs simply being larger on average — a neat demonstration of how easy it is to confuse environment with demographics. This is an ecological correlation across 51 state-level data points, not an individual causal analysis. The next phase will link environmental data like air quality and chemical exposure to individual dogs to hunt for shared factors. 🐕

6. A 43-year observational study on coffee and cognitive health has some new findings

As reported by Science Daily , a 43-year observational study found that drinking 2–3 cups of caffeinated coffee daily was associated with significantly lower dementia risk and better cognitive function — and this association showed up across people with different genetic risk profiles. Decaf coffee didn’t show the same association. The source only provides abstract-level information; specific sample size, journal, and institution still need to be verified. Observational research can’t confirm causation — correlation doesn’t mean coffee is directly reducing dementia risk. ☕

7. The NHS is trialing an AI phone assistant to monitor osteoporosis patients

As reported by Medical Xpress , the UK’s National Health Service is piloting an AI virtual assistant called Dora Care, which uses phone check-ins to help clinicians track osteoporosis patients — a chronic condition that makes bones brittle, affecting around 3.5 million people in the UK, particularly women and those over 50. The program is still in trial phase; the source doesn’t provide enrollment numbers, trial design, or efficacy data. Whether this actually improves patient outcomes is still an open question. 📞

8. Psilocybin rapidly rewires neural connections in stress-damaged mouse brains in a different way than it does in healthy ones

As reported by Science Daily , researchers found that psilocybin — the active compound in psychedelic mushrooms — drives different patterns of neural remodeling in healthy mice versus chronically stressed ones, rapidly building and strengthening new neural connections in stress-damaged brains. The researchers also identified a way to trigger this neural remodeling without producing the hallucinogenic behavioral response. The source is abstract-level; specific mechanisms, sample sizes, and the journal still need to be verified. Results are currently mouse-only — applicability to human cognition or aging intervention is still unclear. 🍄

9. Women with Parkinson’s disease have higher rates of overlapping Alzheimer’s pathology than men

As reported by News-Medical , new research found that the brain pathological changes of Parkinson’s and Alzheimer’s disease can overlap — and this overlap occurs at a higher rate in female patients than in male patients. The cross-pathology between the two neurodegenerative diseases may affect symptom presentation and treatment response, but the source is abstract-level; specific sample size, methodology, and journal need to be verified. 🧠

10. Sironax’s neuroprotective drug SIR2501 reports early safety signals in ALS and chemo-induced nerve damage trials

As reported by Longevity.Technology , SIR2501 from Sironax is a SARM1 inhibitor — SARM1 being the key enzyme that drives nerve fiber degeneration. The drug works by binding to an inactive site on the enzyme to keep it switched off, aiming to avoid the side effects that might come from directly blocking the active site. A poster at the November Neuroscience Annual Meeting reported “favorable safety and early bioactivity signals” in ongoing Phase 1/2 trials for ALS and chemotherapy-induced peripheral neuropathy (the numbness and pain in hands and feet that follows chemo). However, the announcement didn’t include patient numbers, dosing details, or any efficacy metrics — safety and efficacy remain unestablished.

⚡ Product & Feature Updates

Digbi Health launches ASRA, an AI collaboration platform that integrates GLP-1 and metabolic health management for employers

As reported by Longevity.Technology , Digbi Health launched the ASRA platform on October 28th, bundling GLP-1 drugs (the widely discussed class of diabetes/weight-loss medications that have gotten a lot of buzz for dramatic weight-loss results in recent years), hormone replacement therapy, and metabolic chronic disease management into a single system for employer and health plan clients. AI agents handle the operational layer — member outreach, engagement reminders, personalized nutrition guidance — while clinical decisions stay with physicians and health coaches. The company says the platform’s data was built up over three years and currently covers around 30 million accessible lives across 300+ employers. That said, ASRA itself has no published outcome data yet, and whether early-program results will carry over to the new platform remains to be seen.

🧪 Frontier Research

Proteomic aging clocks: a protein module that tracks biological age across cohorts

GEN is hosting an upcoming webinar (December 1st) showcasing an aging clock built from proteomics — the large-scale measurement of protein abundance in blood. Xiao-Jun Ma’s team identified an “intrinsic protein module” across three independent cohorts that correlates with mortality, cognitive function, and comorbidity burden, and can be compared against DNA methylation clocks (the method of estimating age from chemical markers on DNA). Michael Corley will present proteomic and epigenetic results from a randomized trial of semaglutide (a GLP-1 drug), including what happens after stopping the drug. This is a webinar preview — raw research data hasn’t been released yet, and specific results won’t be verifiable until the event. 🔬

⌘ Top Open Source Projects

Gladyshev-Lab/tAge: an R package for estimating biological age from transcriptomic data

tAge is an R package released by Harvard’s Gladyshev Lab for analyzing biological age based on transcriptomic data — the overall pattern of gene expression in cells. It’s aimed at researchers with an R background who are working with RNA sequencing data. The repo had active commits on November 6, 2026 (29 stars). For specific input formats and dependency requirements, check the repo homepage — license status is still to be verified.

msbCyricTohoku/BACalc: a dataset-agnostic dynamic biological age calculator

BACalc proposes a “dataset-agnostic” approach to biological age estimation — meaning the algorithm isn’t locked to a specific training set, and theoretically can be adapted to physiological or molecular data from different sources. The repo was last active on November 2, 2026 (1 star). It’s a good fit for researchers who want to explore biological age estimation methods on their own data. For specific input formats and runtime dependencies, check the repo documentation — license status is still to be verified.

❓ Related Questions

Do the NOVOS Core trial results actually prove this supplement extends lifespan?

Short answer: nope. The trial measured vascular function markers — arterial dilation and blood pressure — which are associated with cardiovascular health, but improved markers don’t prove a reduction in heart attacks or extended lifespan. On top of that, the trial was small (just 43 people in the primary analysis), nearly a third of participants dropped out, the two groups had an average age difference of about seven years, and the study was co-funded by the manufacturer. Both the researchers themselves and outside commentators have explicitly said independent replication is needed before anyone can draw robust conclusions. ⚠️